contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-0204-gubra-pharma-equity-group-wirtek-expres2ion-biotechnologies-og-spar-nord-bank

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Head of Equities

Michael Friis

Head of Research, Stables

Rasmus Køjborg

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.

Gubra

Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.

Pharma Equity Group

WirTek is an IT company. The company focuses on the development of software and hardware solutions that affect web, mobile, and integrated complete systems. The company operates worldwide, with the largest presence in the Nordic region and Europe, where customers mainly consist of small and medium-sized corporate customers. WirTek was founded in 2001 and is headquartered in Aalborg.

Wirtek

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

Biotekdirektør smager egen medicin: Deltager i klinisk forsøg med coronavaccine Adm. direktør Bent U. Frandsen fra biotekselskabet Expres2ion er blandt de 3000 frivillige, der har meldt sig til at deltage i vaccineselskabet Bavarian Nordics fase 3-forsøg med deres fælles udviklede covid-19 vaccine. Tidligere på ugen fik topchefen et vaccinestik. Jeg synes det er for cool!, men også meget tilfældigt med selve udvælgelsen. Du kan læse hele Bents egen kommentar her:                   linkedin.com              Bent Frandsen on LinkedIn: #covid19vaccine #clinicalstudy #phase3 | 16 comments    👍🏻 GETTING A TASTE OF MY OWN MEDICINE 👏🏻  This week I got a shot of COVID-19 vaccine in the ABNCoV2 Phase 3 clinical study in Denmark. How often do... 16 comments on LinkedIn

ExpreS2ion Biotechnologies offentliggjorde i morges deres tal for deres Q3 rapport, hvor de i den forbindelse afholdte en præsentation af netop denne for 2022. Jeg synes det var et spændende event, hvor de både nåede ind på deres resultater, mens de også tog et dybere kig på deres omkostninger. Dernæst nåede de ogå omkring deres Covid-19 vaccinekandidat og tog et kig på markedet som helhed. Afsluttende snakkede de desuden om nogle af de andre produktkandidater, som de har i deres pipeline

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  ExpreS2ion er en biotekvirksomhed med base i Danmark, men børsnoteret i Sverige. Virksomheden udvikler en portefølje af vacciner mod sygdomme som COVID-19, influenza og brystkræft gennem brugen af dets cellebaserede ekspressionssystem, ExpreS2, som er anerkendt for at håndtere protein udfordringer. ExpreS2ion har udviklet Expres2, som er en teknologiplatform til effektiv og hurtig ikke-klinisk udvikling og produktion af komplekse proteiner til nye vacciner og diagnostik. På nuværende tidspunkt er selskabets primære produkt corona-vaccinekandidaten, ABNCoV2 som er i fase 2, udviklet sammen med sin partner, AdaptVac, hvoraf ExpreS2ion ejer 34%. Vaccinekandidatens licensret tilhører Bavarian Nordic som har globale kommercialiseringsrettigheder og ansvar for yderligere klinisk udvikling af vaccinen. English:  ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34% of. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Spar Nord Bank conducts banking operations. The company offers a wide range of financial services to both private and corporate customers, which includes mortgages, private savings, pensions, and insurance, as well as asset management. A large part of the service is handled digitally via the bank's mobile bank. Spar Nord Bank was originally founded in 1824 and is headquartered in Aalborg, Denmark.

Spar Nord Bank

Dagens aktienyheder med Gubra, Pharma Equity Group, Wirtek, ExpreS2ion Biotechnologies og Spar Nord Bank

Dagens aktienyheder 02/04: Gubra, Pharma Equity Group, Wirtek, ExpreS2ion Biotechnologies og Spar Nord Bank
Gubra: Kunne annoncerer to nyheder i g&#xe5;r, den f&#xf8;rste er positive data fra f&#xf8;rste del af Fase-1 studiet MAD for GUBamy - l&#xe6;s mere her: <a href="https://www.inderes.dk/analyst-comments/gubra-offentliggor-positive-data-fra-fase-1-mad-resultater-for-gubamy" target="_blank" rel="noopener">MAD data p&#xe5; GUBamy</a> og den anden g&#xe6;lder godkendelsen af partneraftalen med ABBvie som nu endelig er plads, da samtlige regulatoriske myndigheder har givet gr&#xf8;nt lys.
Pharma Equity Group: Udsteder konvertibelt l&#xe5;n - l&#xe6;s mere her: <a href="https://www.inderes.dk/analyst-comments/pharma-equity-group-udstedelse-af-konvertibelt-lan" target="_blank" rel="noopener">Konvertibelt l&#xe5;n</a>
Wirtek kunne i g&#xe5;r annoncere en aftale om at levere en front-end l&#xf8;sning til en platform der i real tid skal monitorere opladning af el-biler. Kundenavnet oplyses ikke, men der n&#xe6;vnes der er tale om en ledende global leverand&#xf8;r af energi og vandl&#xf8;sninger. L&#xe6;s mere her:&#xa0;<a href="https://www.inderes.dk/releases/wirtek-as-wirtek-delivers-secure-front-end-for-ev-charging-platform" target="_blank" rel="noopener">Wirtek ny order</a>
ExpreS2ion Biotechnologies opdaterede i g&#xe5;r markedet p&#xe5; deres pipeline. Til trods for forventninger om, at have doseret den f&#xf8;rste patient i deres fase 1 brystkr&#xe6;ft vaccine fors&#xf8;g i f&#xf8;rste kvartal, er dette ikke n&#xe5;et ved kvartalets udgang. Desuden meddelte selskabet, at de stopper udviklingen af deres CMv kandidat, et samarbejde med Evaxion Biotech. Dette sker for at fokusere deres forskning p&#xe5; de mest relevante kandidater, og for at sikre en s&#xe5; lang tidshorisont p&#xe5; kapitalen. L&#xe6;s mere her: <a href="https://www.inderes.dk/analyst-comments/expres2ion-biotechnologies-pipeline-update-on-cmw-and-es2b-c001" target="_blank" rel="noopener">ExpreS2ion Biotechnologies</a>
Spar Nord meddeler her til morgen at Nykredit har forl&#xe6;nget tilbudsperioden til aktion&#xe6;rerne i Spar Nord frem til og med torsdag d. 24. april 2025. Det er den tredje forl&#xe6;ngelse af tilbudsperioden som oprindeligt l&#xf8;b fra d. 8. januar. I dagens meddelelse forh&#xf8;jer Nykredit buddet med DKK 0,5 per aktie til DKK 210,50 L&#xe6;s hele meddelelsen her: <a href="https://media.sparnord.dk/com/investor/finansiel_kommunikation/tilbud/nr-9-nykredit-offentliggoer-forlaengelse-af-tilbudsperioden.pdf" target="_blank" rel="noopener">Forl&#xe6;ngelse af budperioden og pris</a>
Disclaimer: HC Anderen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR/Corporate Visibility abonnementsaftale.
/Claus Thestrup d. 02/04-2025 kl. 9:13.

Dagens aktienyheder 02/04: Gubra, Pharma Equity Group, Wirtek, ExpreS2ion Biotechnologies og Spar Nord Bank

Questionnaire about Gubra

The company is a good long-term investment

The company has strong competitive advantages

The company's management is reliable

Privacy preferences